Galectin Therapeutics, Inc. (GALT)
3.69
-0.18
(-4.65%)
USD |
NASDAQ |
Oct 13, 10:40
Galectin Therapeutics Net Income (TTM) : -27.84M for June 30, 2026
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -27.84M |
| March 31, 2026 | -26.25M |
| December 31, 2025 | -30.84M |
| September 30, 2025 | -37.30M |
| June 30, 2025 | -40.34M |
| March 31, 2025 | -45.19M |
| December 31, 2024 | -47.05M |
| September 30, 2024 | -45.08M |
| June 30, 2024 | -44.28M |
| March 31, 2024 | -41.03M |
| December 31, 2023 | -41.07M |
| September 30, 2023 | -41.70M |
| June 30, 2023 | -39.87M |
| March 31, 2023 | -40.37M |
| December 31, 2022 | -38.78M |
| September 30, 2022 | -35.36M |
| June 30, 2022 | -35.29M |
| March 31, 2022 | -34.12M |
| December 31, 2021 | -30.53M |
| September 30, 2021 | -31.16M |
| June 30, 2021 | -28.58M |
| March 31, 2021 | -26.25M |
| December 31, 2020 | -23.46M |
| September 30, 2020 | -20.75M |
| June 30, 2020 | -17.59M |
| Date | Value |
|---|---|
| March 31, 2020 | -14.48M |
| December 31, 2019 | -13.29M |
| September 30, 2019 | -11.21M |
| June 30, 2019 | -11.18M |
| March 31, 2019 | -12.02M |
| December 31, 2018 | -13.90M |
| September 30, 2018 | -13.23M |
| June 30, 2018 | -14.89M |
| March 31, 2018 | -15.56M |
| December 31, 2017 | -16.24M |
| September 30, 2017 | -18.44M |
| June 30, 2017 | -18.56M |
| March 31, 2017 | -19.57M |
| December 31, 2016 | -21.44M |
| September 30, 2016 | -21.52M |
| June 30, 2016 | -22.88M |
| March 31, 2016 | -22.00M |
| December 31, 2015 | -20.03M |
| September 30, 2015 | -19.14M |
| June 30, 2015 | -16.83M |
| March 31, 2015 | -15.62M |
| December 31, 2014 | -15.96M |
| September 30, 2014 | -15.03M |
| June 30, 2014 | -15.00M |
| March 31, 2014 | -22.87M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (TTM) Benchmarks
| Mirum Pharmaceuticals, Inc. | -860.21M |
| ACADIA Pharmaceuticals, Inc. | 380.48M |
| Alnylam Pharmaceuticals, Inc. | 807.99M |
| Anika Therapeutics, Inc. | -3.121M |
| Savara, Inc. | -139.31M |